Welcome to our dedicated page for Vertex Pharmaceuticals news (Ticker: VRTX), a resource for investors and traders seeking the latest updates and insights on Vertex Pharmaceuticals stock.
Vertex Pharmaceuticals Inc (VRTX) is a global biopharmaceutical leader focused on transformative therapies for serious diseases. This page serves as the definitive source for all official Vertex news, including regulatory milestones, clinical developments, and strategic partnerships.
Investors and researchers will find timely updates on cystic fibrosis treatment advancements, gene-editing therapy progress, and pipeline expansions into pain management and blood disorders. Our curated feed includes earnings announcements, FDA submissions, and peer-reviewed research publications.
The repository features three core categories: Treatment Approvals (new drug applications and label expansions), Research Breakthroughs (clinical trial results and preclinical discoveries), and Strategic Developments (collaborations and manufacturing updates). Each entry provides direct access to primary source materials.
For ongoing monitoring of Vertex's innovations in small-molecule drugs and CRISPR-based therapies, bookmark this page or check back regularly. All content is vetted against original company disclosures to ensure regulatory compliance and factual accuracy.
Vertex Pharmaceuticals presented long-term data for CASGEVY™, their CRISPR/Cas9 gene-edited therapy, showing sustained benefits in treating severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). Key findings include:
- 93% of SCD patients (39/42) remained free from vaso-occlusive crises for at least 12 months, with mean duration of 30.9 months
- 98% of TDT patients (53/54) achieved transfusion-independence for at least 12 months with adequate hemoglobin levels
The company has activated over 45 treatment centers globally and collected cells from more than 40 patients. CASGEVY is now approved in multiple countries, including the U.S., EU, and UK, with reimbursement agreements secured in several regions.
Vertex Pharmaceuticals reported strong Q3 2024 results with product revenue of $2.77 billion, up 12% year-over-year. The company raised its full-year 2024 product revenue guidance to $10.8-10.9 billion. Q3 performance was driven by TRIKAFTA/KAFTRIO's continued strong performance, with U.S. revenue up 10% to $1.71 billion and international revenue up 14% to $1.06 billion. The company is preparing for two potential near-term launches: vanzacaftor triple in CF and suzetrigine for acute pain. Three additional programs advanced to Phase 3: suzetrigine in DPN, povetacicept in IgAN, and VX-880 in T1D.
Vertex Pharmaceuticals (Nasdaq: VRTX) has announced its management's participation in two upcoming investor conferences in November 2024. Dr. Reshma Kewalramani, CEO and President, will join a fireside chat at the Guggenheim Inaugural Healthcare Innovation Conference on November 12 at 9:00 a.m. ET. Stuart A. Arbuckle, Executive Vice President and COO, will participate in the Stifel Healthcare Conference on November 19 at 8:00 a.m. ET. Both sessions will be available via live webcast on the company's website, with replays archived in the Investors section.
Vertex Pharmaceuticals shared updates on multiple kidney disease programs at ASN Kidney Week Congress. New data shows povetacicept achieved 66% mean UPCR reduction at 48 weeks in IgA nephropathy patients, with 63% reaching clinical remission. In primary membranous nephropathy, povetacicept demonstrated 62% mean UPCR reduction at 24 weeks. The company launched the global Phase 3 RAINIER trial for IgA nephropathy and continues enrollment in Phase 3 AMPLITUDE trial of inaxaplin for APOL1-mediated kidney disease. Both treatments were well-tolerated with mostly mild to moderate adverse events.
Vertex Pharmaceuticals (Nasdaq: VRTX) will present Phase 3 data on suzetrigine, an investigational oral NaV1.8 pain signal inhibitor, at the American Society of Anesthesiologists (ASA) Annual Meeting in October 2024. The data, selected for the "Best Abstract" session, demonstrates compelling efficacy and safety across multiple acute pain conditions. Two randomized, placebo-controlled trials and a single-arm safety study will be presented, marking the first public presentation of these positive results announced in January 2024.
Suzetrigine aims to be the first non-opioid acute pain treatment in over two decades. Vertex has also initiated a Phase 3 program for suzetrigine in painful diabetic peripheral neuropathy and expects results from a Phase 2 study in painful lumbosacral radiculopathy in late 2024. An investor event will be held on October 20, 2024, to discuss the Phase 3 results in acute pain.
Vertex Pharmaceuticals (Nasdaq: VRTX) has announced that it will release its third quarter 2024 financial results on Monday, November 4, 2024, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET to discuss the results.
Interested parties can access the call by dialing (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and referencing the "Vertex Pharmaceuticals Third Quarter 2024 Earnings Call." A live webcast link will be available on Vertex's website in the "Investors" section. Participants are advised to register at least 15 minutes before the scheduled webcast to ensure a timely connection. An archived version of the webcast will be made available on the company's website for those unable to attend the live event.
Vertex Pharmaceuticals (Nasdaq: VRTX) announced the first oral presentation of Phase 3 data on their investigational vanzacaftor/tezacaftor/deutivacaftor (vanza triple) at the North American Cystic Fibrosis Conference (NACFC). The vanza triple demonstrated non-inferiority to TRIKAFTA® in ppFEV1 and further improvement in CFTR function as measured by sweat chloride. Vertex also presented data showing sustained long-term benefits of TRIKAFTA®, including improvement in pancreatic function in young patients.
The vanza triple has been submitted for regulatory approval in multiple countries, with an FDA PDUFA date of January 2, 2025. New data on TRIKAFTA® from long-term studies in patients ages 2-11 years old showed sustained improvements in lung function and potential improvement in exocrine pancreatic function over time.
Vertex Pharmaceuticals (Nasdaq: VRTX) has announced its participation in two upcoming investor conferences in September 2024. Dr. Reshma Kewalramani, CEO and President, and Charles Wagner, EVP and CFO, will engage in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on September 5 at 11:30 a.m. ET. Additionally, Susie Lisa, SVP of Investor Relations, and Manisha Pai, Executive Director of Investor Relations, will participate in a fireside chat at the Cantor Global Healthcare Conference on September 17 at 9:10 a.m. ET.
Both events will be webcast live through the Vertex website's Investors section. Replays of the conference webcasts will be archived on the company's website for future reference.
Vertex Pharmaceuticals has secured a reimbursement agreement with NHS England for eligible transfusion-dependent beta thalassemia (TDT) patients to access CASGEVY™, a CRISPR/Cas9 gene-edited therapy. This agreement follows positive guidance from NICE recommending CASGEVY's use in the NHS. The therapy received the world's first authorization for a CRISPR-based gene-editing treatment from the UK's MHRA on November 15, 2023.
Vertex is establishing a network of authorized treatment centers throughout England for therapy administration. The company is also working to ensure access for eligible sickle cell disease patients in England and collaborating with reimbursement authorities in the EU to bring this innovative therapy to eligible SCD and TDT patients in other regions.
Vertex Pharmaceuticals (Nasdaq: VRTX) announced its Q2 2024 financial results, reporting a 6% increase in product revenue to $2.65 billion compared to Q2 2023. The company has raised its full-year product revenue guidance to $10.65-$10.85 billion. Significant regulatory milestones were achieved, including FDA Priority Reviews for Vanzacaftor triple therapy in cystic fibrosis (CF) and Suzetrigine for acute pain with target action dates in January 2025.
Net product revenue rose 7% in the U.S. and 5% internationally. However, Vertex reported GAAP and non-GAAP net losses of $3.6 billion and $3.3 billion, respectively, due to $4.4 billion in acquired in-process R&D expenses linked to its acquisition of Alpine Immune Sciences. Despite this, the company remains committed to advancing a robust clinical pipeline, with multiple milestones expected in H2 2024, including the launch of CASGEVY for sickle cell disease and transfusion-dependent beta thalassemia.
Vertex's cash and equivalents decreased to $10.2 billion, reflecting the Alpine acquisition cost. The company expects combined GAAP R&D and SG&A expenses to range from $5.0-$5.2 billion for 2024.
FAQ
What is the current stock price of Vertex Pharmaceuticals (VRTX)?
What is the market cap of Vertex Pharmaceuticals (VRTX)?
